Dosologic: a precision dosing software optimising chemotherapy for children.

点击翻译按钮获取中文摘要

**Who is Vesynta?**A personalised medicine company that delivers data-guided precision dosing via rapid patient monitoring.**Who are we helping?**The 400,000 children diagnosed with cancer globally each year.**What's the challenge?**Choosing the optimal chemotherapy dose. Many factors (fat distribution/organ function/enzyme availability, etc.) affect how drugs are metabolised and cleared from our bodies. These differences are exaggerated in children due to their rapidly developing anatomy.**What does this mean in practice?**Two people given the same dose may have very different "drug-exposures" i.e. concentration of a drug in the blood and the length of time it stays there.**Which drugs is this a problem for?**Drugs used to treat critical illnesses, including chemotherapeutics. If drug exposure is too low, cancer will continue to grow. Whereas, if drug exposure is too high the patient may suffer from toxic side effects.**How have clinicians dealt with this?**Until now, the patient's weight or surface area is used to determine the chemotherapy dose. This does not dynamically capture the entire clinical complexity of an individual patient.**How could we improve?**Provide access to evidence that supports chemotherapy dose adjustments towards a "target drug exposure". By measuring drug concentrations from blood samples taken over time, we can predict the right dose to achieve the optimum drug exposure.**Is this difficult?**Each dose adjustment requires pharmacology expertise and processing of clinical data. However, with intelligent software that complements a point-of-care monitoring device, this level of personalisation could become standard of care for all.**What will the software do?**It will use concentration data to build a unique "pharmacokinetic" model for each patient. A user-friendly bedside interface will support clinicians to deliver the optimal dose every time, making personalised childhood cancer treatment more safe, effective and precise.**Can we deliver?**Our team includes world-leading engineers, pharmacologists, entrepreneurs, and paediatric oncologists. NIHR-funding already supports development of our drug monitoring hardware. Dosologic now develops a precision dosing software to create a "Dose-Measure-Learn" precision dosing loop.**When will I see this in action?**Our innovation pipeline will require rigorous testing and regulatory approval, entering the clinical setting in 2024\.**Who else benefits from personalised dosing?**Any patient group that requires tailored treatment due to clinical trial under-representation (elderly, women, ethnic minorities, patients with rare disease). Healthcare providers, families and the wider economy all benefit from fewer toxic events and enhanced quality of life for children with cancer.